The upgrade from Underweight to Equal-Weight suggests that Morgan Stanley sees potential in C4 Therapeutics. However, the lowering of the price target from $3 to $1 indicates a potential decrease in the stock's value. This mixed signal could lead to uncertainty in the market, potentially keeping the stock's price stable in the short term.